ChemBriefBIO CEO Calls for Greater Consistency in FDA Drug Review Process
BIO CEO John Crowley urges the FDA to standardize drug application reviews to reduce uncertainty, particularly for rare diseases, as part of broader efforts to accelerate clinical trials and maintain
reuters · 2026-06-23 13:34